Globecast Extends Partnership with SES for Distribution Services to Orange Romania
Globecast, the global solutions provider for media, has extended its partnership with SES for the premium TV distribution services it provides to Orange Romania using SES’s satellite capacity.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180107005143/en/
Globecast will lease several transponders on ASTRA 5B to serve Orange Romania, which uses the capacity to broadcast 112 channels (Photo: Business Wire)
Under the multi-year extension announced by SES, Globecast will lease several transponders on ASTRA 5B at 31.5 degrees East to serve Orange Romania, which uses the capacity to broadcast 112 channels, of which 52 are in HD, using the DVB-S2 and MPEG-4 technical standards. Globecast manages the contribution, encryption and encoding for the entire TV package, as well as signal transport to the uplink facilities for ASTRA 5B.
Orange Romania’s premium TV offer was launched in June 2013 with the support of SES, leveraging the high power and wide coverage of the ASTRA 5B satellite to deliver HD channels via the smallest dish in the Romanian market. In a highly competitive TV market, with 98 percent pay-TV coverage and five operating DTH platforms, Orange TV’s satellite platform has grown exponentially since its launch.
“We’ve worked extensively with SES and this is another example of the benefits of this partnership for our customers. In such a competitive market, quality of service is an essential factor in determining success, and we are pleased to extend this specific part of the relationship,” said Biliana Pumpalovic, General Director of Globecast in Moscow.
“This extension agreement highlights the role of satellite as vital infrastructure for telecommunications operators to deliver television packages to their subscribers,” said Martin Ornass-Kubacki, Vice President and Chief Regional Officer, at SES Video. “We have been supporting Orange Romania for its DTH service since the beginning, not only from a technical point of view but also in the area of marketing, to promote their offer to the entire country. We are very pleased to continue working with such an innovative partner and enable them to deliver high-quality service to their consumers.”
“Our customers’ experience is at the forefront of all the services we supply to our customers, be it the most extensive 4G network in the country or the content that we provide access to. We are proud to bring Orange Love convergent packs to all households by offering satellite television in addition to our fiber offer. The extension of the partnership with Globecast and SES fits right in with this strategy,” said Yves Martin, Chief Marketing Officer at Orange Romania.
Globecast helps customers to manage content and to deliver it wherever, however and whenever required. The company provides agile and seamless content acquisition, management and distribution services globally, constantly innovating and investing in new technologies to create customer-centric new services. Globecast has created the number one global hybrid fiber and satellite network for video contribution and distribution. It delivers any type of video service including: TV Everywhere OTT, satellite, cable, video-on-demand and CDN delivery using cloud-enabled media solutions. It supplies Content Acquisition, Aggregation and Distribution (CAAD) services to over 110 networks.
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com
Follow us on:
About Orange Romania
Orange is the mobile telecom leader in Romania with 10.331.000 customers and revenues of 277,2 million euros on September 30th 2017. Orange Romania is part of the Orange Group, one of the world’s leading telecommunications operators, with over 269 million customers worldwide. Orange Romania offers a wide range of communications solutions to its customers, both individual users and companies, from basic services to voice, data, fixed and mobile complete services, as well as TV services. Orange is also a leading provider of global IT and telecommunication services to multinational companies, under the brand Orange Business Services. In March 2015, the Group presented its new strategic plan “Essentials2020” which places customer experience at the heart of its strategy with the aim of allowing them to benefit fully from the digital universe and the power of its new generation networks. More details about the company's products and services are available at www.orange.ro.
For further information please contact:
Corporate Communications & PR
Tel. +352 710 725 500
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 20:30 | Pressemelding
Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00 | Pressemelding
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53 | Pressemelding
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00 | Pressemelding
Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07 | Pressemelding
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17 | Pressemelding
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr